Suggested remit: To appraise the clinical and cost effectiveness of ciltacabtagene autoleucel within its marketing authorisation for treating relapsed and lenalidomide-refractory multiple myeloma after at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- None selected
- Process:
- STA Standard
- ID number:
- 4012
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators:
- 08 May 2026 - 08 June 2026
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 March 2026 | In progress. Following discussions with the company, this appraisal has been scheduled back into the work programme. The appraisal is expected to begin in early July 2026. |
| 08 March 2024 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 20 October 2023 | Note - Note added to the project documents |
| 12 April 2023 | Note - Note added to the project documents |
| 25 October 2022 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual